Corporate Presentations


Corporate Research Report


ASCO 2022


ESMO 2022



ECHNO 2023


ESTRO 2023


ESMO 2023


Corporate Interviews & Videos

Screenshot 2025-03-26 at 11.53.40 AM
March 3, 2025
Geert Kersten discusses how CEL-SCI is taking a critical step forward in the fight against head and neck cancer with the initiation of the Multikine Confirmatory Phase 3 Trial—a pivotal study that could bring this innovative immunotherapy one step closer to FDA approval and commercialization.
Screen Shot 2024-11-26 at 11.21.04 AM
November 22, 2024
Geert Kersten discusses the implications of the FDA’s Oncologic Drugs Advisory Committee (ODAC) decision on checkpoint inhibitors for patients with low or negative PD-L1 expression and the significance to CEL-SCI.
Screen Shot 2024-10-25 at 10.05.33 AM
October 21, 2024
An interview with Geert Kersten discussing the unique approach CEL-SCI has to fight cancer.
Screen Shot 2023-10-24 at 2.00.24 PM
October 23, 2023
A presentation delivered by Geert Kersten Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals.
Screen Shot 2022-10-19 at 9.31.10 AM
September 2022
An oral presentation delivered by Dr. Philip Lavin of groundbreaking tumor response and increased overall survival in head and neck cancer. This presentation includes data presented at the European Society for Medical Oncology (ESMO) Annual Congress in September 2022.
Accessibility by WAH